The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European Food Safety Authority was requested to evaluate the genotoxic potential of six flavouring substances from subgroup 4.6 of FGE.19 in the Flavouring Group Evaluation 222. The Flavour Industry have provided additional genotoxicity studies for two representative substances, 3-(2-furyl)acrylaldehyde .034] and 4-(2-furyl)but-3-en-2-one [FL-no: 13.044], in FGE.222. Based on these new data the Panel could not rule out a clastogenic and aneugenic potential for the two substances and a in vivo Comet assay was requested for both substances, the one including a micronucleus assay. © European Food Safety Authority, 2012
lays down a Procedure for the establishment of a list of flavouring substances, the use of which will be authorised to the exclusion of all other substances in the EU. In application of that Regulation, a Register of flavouring substances used in or on foodstuffs in the Member States was adopted by Commission Decision 1999/217/EC (EC, 1999a), as last amended by Commission Decision 2009/163/EC (EC, 2009a) . Each flavouring substance is attributed a FLAVIS-number (FL-number) and all substances are divided into 34 chemical groups. Substances within a group should have some metabolic and biological behaviour in common.
Substances which are listed in the Register are to be evaluated according to the evaluation programme laid down in Commission Regulation (EC) No 1565 /2000 (EC, 2000a , which is broadly based on the Opinion of the Scientific Committee on Food (SCF, 1999a) . For the submission of data by the manufacturer, deadlines have been established by Commission Regulation (EC) No 622/2002 (EC, 2002b .
After the completion of the evaluation programme the Union list of flavouring substances for use in or on foods in the EU shall be adopted (Article 5 (1) of Regulation (EC) No 2232/96) (EC, 1996a) .
Flavouring Group Evaluation 19 (FGE.19) contains 360 flavouring substances from the EU Register being α,β-unsaturated aldehydes or ketones and precursors which could give rise to such carbonyl substances via hydrolysis and/or oxidation (EFSA, 2008b) .
The α,β-unsaturated aldehyde and ketone structures are structural alerts for genotoxicity. The Panel noted that there were limited genotoxicity data on these flavouring substances but that positive genotoxicity studies were identified for some substances in the group.
The α,β-unsaturated carbonyls were subdivided into 28 subgroups on the basis of structural similarity (EFSA, 2008b) . In an attempt to decide which of the substances could go through the Procedure, a (quantitative) structure-activity relationship (Q)SAR prediction of the genotoxicity of these substances was undertaken considering a number of models (DEREKfW, TOPKAT, DTU-NFI-MultiCASE Models and ISS-Local Models (Gry et al., 2007) ).
The Panel noted that for most of these models internal and external validation has been performed, but considered that the outcome of these validations was not always extensive enough to appreciate the validity of the predictions of these models for these α,β-unsaturated carbonyls. Therefore, the Panel considered it inappropriate to totally rely on (Q)SAR predictions at this point in time and decided not to take substances through the procedure based on negative (Q)SAR predictions only.
The Panel took note of the (Q)SAR predictions by using two ISS Local Models (Benigni and Netzeva, 2007a; Benigni and Netzeva, 2007b) and four DTU-NFI MultiCASE Models (Gry et al., 2007; Nikolov et al., 2007) and the fact that there are available data on genotoxicity, in vitro and in vivo, as well as data on carcinogenicity for several substances. Based on these data the Panel decided that 15 subgroups (1.1.1, 1.2.1, 1.2.2, 1.2.3, 2.1, 2.2, 2.3, 2.5, 3.2, 4.3, 4.5, 4.6, 5.1, 5.2 and 5. 3) (EFSA, 2008b) could not be evaluated through the Procedure due to concern with respect to genotoxicity. Corresponding to these subgroups, 15 Flavouring Group Evaluations (FGEs) were established, FGE.200, 204, 205, 206, 207, 208, 209, 211, 215, 219, 221, 222, 223, 224 and 225) .
For 11 subgroups the Panel decided, based on the available genotoxicity data and (Q)SAR predictions, that a further scrutiny of the data should take place before requesting additional data from the Flavouring Industry on genotoxicity. These subgroups were evaluated in FGE.201, 202, 203, 210, 212, 213, 214, 216, 217, 218 and 220 . For the substances in FGE.202, 214 and 218 it was concluded that a genotoxic potential could be ruled out and accordingly these substances will be evaluated using the Procedure. For all or some of the substances in the remaining FGEs, FGE.201. 203, 210, 212, 213, 216, 217 and 220 the genotoxic potential could not be ruled out.
To easy the data retrieval of the large number of structurally related α,β-unsaturated substances in the different subgroups for which additional data are requested, EFSA has worked out a list of representative substances for each subgroup (EFSA, 2008bc) . Likewise an EFSA genotoxicity expert group has worked out a test strategy to be followed in the data retrieval for these substances (EFSA, 2008bb) .
The Flavouring Industry has been requested to submit additional genotoxicity data according to the list of representative substances and test strategy for each subgroup.
The Flavouring Industry has now submitted additional data on representative substances of subgroup 4.6 and the present FGE concerns the evaluation of these data requested on genotoxicity.
TERMS OF REFERENCE AS PROVIDED BY THE COMMISSION
European Food Safety Authority (EFSA) is requested to carry out a risk assessment on flavouring substances prior to their authorisation and inclusion in a Union list according to Commission Regulation (EC) No 1565/2000 (EC, 2000a) .
In addition, in letter of 23 January 2012, the European Commission requests the European Food Safety Authority to carry out a safety assessment on the following six substances, 3- (2- Table 6 .
All six substances have previously been evaluated by the JECFA at their 65 th and 69 th meetings (JECFA, 2006b; JECFA, 2009c) . At the latest meeting it was concluded "that the Procedure could not be applied to this group because of the unresolved toxicological concerns". A summary of their current evaluation status by the JECFA and the outcome of this consideration is presented in Table 7 .
The α,β-unsaturated aldehyde and ketone structures are considered to be structural alerts for genotoxicity (EFSA, 2008b) and the data on genotoxicity previously available did not rule out this concern for genotoxicity.
Representative substances for subgroup 4.6
The Panel has identified two substances in subgroup 4.6 which will represent the other four substances in this subgroup (EFSA, 2008bc) . For these two substances genotoxicity data according to the test strategy (EFSA, 2008bb) have been requested. The representative substances are listed in Table 1 . The Industry has submitted data concerning genotoxicity studies for the two representative substances for this subgroup (EFFA, 2011q). -no: 13 .044].
2.1.

In vitro data
In vitro genotoxicity assays have been performed on both representative substances. (Whitwell, 2010d) (Table 8) .
Cells were stimulated with phytohaemagglutinin (PHA) and then treated for 3 hours (followed by 21 hours recovery) with 0, 50, 75, 120 and 150 μg/ml of 3-(2-furyl)acrylaldehyde in the absence of S9 and 0, 50, 65 and 90 μg/ml in the presence of S9, respectively. The levels of toxicity (reduction in replication index) at the top concentrations in the absence and presence of S9 were 61 and 59 %, respectively. In a parallel assay, cells were treated with 0, 25, 30 and 40 μg//ml of 3-(2furyl)acrylaldehyde for 24 hours in the absence of S9 with no recovery period. In this assay, the top concentration induced 55 % cytotoxicity ( To further investigate the conditions under which the statistically significant increases were observed, 3-(2-furyl)acrylaldehyde was re-tested with the 3 + 21 hours treatment in the presence of S9 (Whitwell, 2011b) (Table 8) .
As shown in Table 3 . In view of the reproducibility of response between two separately conducted studies, the small but statistically significant increases in MNBN, observed also at levels not excessively toxic in the presence of S9, were considered indicative of a weak clastogenic or aneugenic potential for 3-(2-furyl)acrylaldehyde .034] in the presence of metabolic activation.
In conclusion, though the micronucleus frequencies mostly felt within historical control ranges, the statistically significant increases were reproducible and therefore considered indicative of a weak clastogenic or aneugenic potential.
The details and conclusions for the Micronucleous assays on 3-(2-furyl)acrylaldehyde described above are summarised in Tables 2, 3 and 8.
4-(2-Furyl)but-3-en-2-one (furfurylidene acetone)
Bacterial Reverse Mutation Assay
Previously available in vitro genotoxicity data 4-(2-Furyl)but-3-en-2-one .044] was reported as non mutagenic in the Ames test using four S. typhimurium strains (TA98, TA100, TA1535 and TA1537) in the presence and absence of the S9 fractions, at concentrations of 0, 33, 100, 333, 1000 and 3333 μg/plate (Mortelmans et al., 1986) . This publication reports the results of the Ames test on 270 chemicals tested by three laboratories under contract to the US. National Toxicology Program (NTP) ( Table 8) .
Additional genotoxicity data 4-(2-Furyl)but-3-en-2-one .044] was tested in a top-up GLP study in S. typhimurium TA102 strain in the presence and absence of S9 up to 5000 micrograms/plate (Kilford, 2010) . Overall the study data, when combined with the published results in four other strains (Mortelmans et al., 1986) , achieve compliance with current OECD recommendations (Table 8) .
As in the Mortelmans et al. study (1986) , no increases in revertant numbers were observed. It was therefore concluded that 4-(2-furyl)but-3-en-2-one, while already shown not to be mutagenic in strains TA98, TA100, TA1535 and TA1537, is neither mutagenic for TA102 at concentrations up to the maximum required which caused bactericidal effects.
2.1.2.2.
In vitro micronucleus assays 4-(2-Furyl)but-3-en-2-one [FL-no: 13.044] was tested in a GLP/OECD in vitro micronucleus assay in human lymphocyte cultures in the absence and presence of S9-mix (Lloyd, 2009b) . The study was performed in compliance with OECD Test Guideline 487 (Table 8) .
After stimulation for 48 hours with phytohaemagglutinin (PHA) cells were treated for 3 hours (followed by 21 hours recovery) with 0, 100, 250 and 300 μg/ml of 4-(2-furyl)but-3-en-2-one in the absence of S9 and 0, 65, 80 and 100 μg/ml in the presence of S9, respectively. The levels of toxicity at the top concentrations in the absence and presence of S9 were 57 and 52 %, respectively. In a parallel experiment, cells were treated with 0, 40, 55 and 65 μg/ml of 4-(2-furyl)but-3-en-2-one for 24 hours in the absence of S9, with no recovery period. In this experiment, the top concentration induced 56 % cytotoxicity (Table 4 ). There were two replicate cultures per treatment and 1000 binucleate cells per replicate (i.e., 2000 cells per concentration) were scored for micronuclei.
As reported in Table 4 with the results summary, at the highest concentration (300 μg/ml) in the 3 + 21 hours treatment in the absence of S9, the MNBN cell frequency (0.75 %, with 57 % cytotoxicity) was significantly (p≤0.01) higher than the concurrent vehicle control (0.15 %), however, it was within the historical control range (0.0 -1.0 %). The MNBN cell frequencies in all other treatment conditions were not statistically significantly increased and fell within the normal ranges.
To further investigate the conditions under which the small statistical increase was observed, 4-(2furyl)but-3-en-2-one was re-tested with the 3+21 hours treatment in the absence of S9-mix (Lloyd, 2011d) .
As reported in Table 5 It was concluded that 4-(2-furyl)but-3-en-2-one .044] induced micronuclei when tested at the top concentrations of 300 and 325 μg/ml for 3 + 21 hours treatment in the absence of metabolic activation (S9) in two independent studies.
The details and conclusions for the Micronucleous assays on 4-(2-furyl)but-3-en-2-one described above are summarised in Tables 4, 5 and 8.
In vivo data
No in vivo data are available for the two representative substances for subgroup 4.6.
Conclusion
3-(2-Furyl)acrylaldehyde .034] was negative in the Ames test. In the in vitro micronucleus assay, statistically significant and reproducible increases in MNBN cells frequencies were observed in two separate studies in the presence of metabolic activation (S9) with the effect observed at modest levels of cytotoxicity. In the first study the increases were seen at the two top concentrations and in the second study, the increases were observed at two intermediate concentrations. Even though the micronucleus frequencies in the treated cells felt in most of the occasions within the historical control ranges, the reproducibility of statistically significant increases in MNBN cells in the presence of S9 in two separate studies, observed at modest levels of cytotoxicity, was considered indicative of a clastogenic or aneugenic potential for 3-(2-furyl)acrylaldehyde.
The Panel considered that in order to clarify the clastogenic and aneugenic potential of 3-(2furyl)acrylaldehyde .034] an in vivo combined Comet and micronucleus assay by oral route in rodents should be performed. As the in vitro effect was observed in the presence of metabolic activation the Comet assay should include an investigation of the liver. The combined study has to be preferred to an in vivo micronucleus assay, in view of the possibility that a genotoxic metabolite of 3-(2-furyl)acrylaldehyde does not reach the target (bone marrow cells) in sufficient amount. .044] was negative in the Ames test. In the in vitro micronucleus assay, statistically significant and reproducible increases in MNBN cells were observed in two separate studies in the absence of metabolic activation (S9) at the top concentration. Though the results observed in the first study felt within the historical control range, the Panel considered that in order to clarify the clastogenic and aneugenic potential of 4-(2-furyl)but-3-en-2-one, an in vivo Comet assay in rodents should be performed. As the in vitro effect was observed in the absence of metabolic activation, the Panel considered an in vivo Comet assay more appropriate than an in vivo micronucleus assay. The Comet assay should include evaluation of first site of contact following oral administration (e.g. stomach or duodenum), since in vitro the effects were observed in the absence of S9 and the micronucleus assay in bone marrow is not appropriate to detect effects occurring in first site of contact tissues.
4-(2-Furyl)but-3-en-2-one
In conclusion the available data do not rule out the concern for genotoxicity. 2) Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 3) Procedure path A substances can be predicted to be metabolised to innocuous products. Procedure path B substances cannot. 4) No safety concern based on intake calculated by the MSDI approach of the named compound. 5) Data must be available on the substance or closely related substances to perform a safety evaluation. ND: not determined. Negative (Lillford, 2010) Toxicity observed in all strains at 1000 and/or 5000 μg/plate or greater in the presence and absence of S-9.
GENOTOXICITY (IN VITRO)
S. typhimurium TA98, TA1535, TA1537 and TA102 0.32, 1.6, 8, 40, 200, 1000 and 5000 μg/plate [1, 2] Negative S. typhimurium TA98, TA100, TA1535, TA1537 and TA102 8.192, 20.48, 51.2, 128, 320, 800, 2000 and 5000 μg/plate [2, 3] Negative Toxicity observed in all strains at 5000 μg/plate in the absence of S-9. 8.192, 20.48, 51.2, 128, 320, 800, 2000 and 5000 μg/plate [4, 5] Negative
Toxicity observed at 800 and 2000 μg/plate in presence of S-9 with preincubation.
Micronucleus induction
Human peripheral blood lymphocytes 50, 75, 120, and 150 μg/ml [3, 6] ; 50, 65 and 90 μg/ml [5, 6] Positive at top 2 concentrations [5] ( Whitwell, 2010d) Complies with OECD guideline 487. Acceptable levels of cytotoxicity were achieved at the top concentrations used in all parts of the study. 25, 30 and 40 μg/ml [3, 7] Negative 55, 70, 95 and 110 μg/ml [5, 6] 78.13, 156.13, 312.5, 625, 1250, 2500 and 5000 μg/plate [2, 3] 
Negative
Toxicity observed in all strains at 2500 μg/plate or greater. 78.13, 156.13, 312.5, 625, 1250, 2500 and 5000 μg/plate [4, 5] Negative S. typhimurium TA98, TA100, 33, 100, 333, 1000, 2166 and 3333 μg/plate [1, 4] Negative (Mortelmans et al., 1986) Human peripheral blood lymphocytes 100, 250, and 300 μg/ml [3, 6] ; 65, 80 and 100 μg/ml [5, 6] Positive only at > 50 % cytotoxicity [3] ( Lloyd, 2009b) Complies with OECD guideline 487. Acceptable levels of cytotoxicity were achieved at the top concentrations used in all parts of the study. 40, 55 and 65 μg/ml [3, 7] Negative 100, 250, 300, and 325 μg/ml [3, 6] Positive only at top concentration, which induced > 50 % toxicity and was too cytotoxic to score in a previous study (Lloyd, 2011d) Complies with OECD guideline 487. Acceptable levels of cytotoxicity were achieved at the top concentrations used in all parts of the study.
